Alnylam Pharmaceuticals, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
ALNY Nasdaq 2830 www.alnylam.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Alnylam Pharmaceuticals, Inc.

CRDF Stock Soars on Robust Efficacy Data From Colorectal Cancer Study - Dec 11th, 2024 3:05 pm
What Makes Alnylam (ALNY) a New Buy Stock - Dec 4th, 2024 5:00 pm
Is Sensus Healthcare (SRTS) Outperforming Other Medical Stocks This Year? - Dec 4th, 2024 2:40 pm
Why Is Alnylam Pharmaceuticals, Inc. (ALNY) Among the Best High Growth Healthcare Stocks to Invest In Now? - Dec 2nd, 2024 7:48 pm
Alnylam to Webcast Presentation at Piper Sandler 36th Annual Healthcare Conference - Nov 27th, 2024 12:00 pm
Kronos, Idorsia plan layoffs; PTC shelves ALS drug - Nov 27th, 2024 10:38 am
FDA Begins Review of Alnylam's sNDA for Expanded Amvuttra Use - Nov 26th, 2024 2:28 pm
BridgeBio Catapults After Snagging Approval For Its Rival To Pfizer's Heart Drug - Nov 25th, 2024 9:16 pm
Exploring Three High Growth Tech Stocks In The United States - Nov 25th, 2024 2:15 pm
Alnylam Announces U.S. Food and Drug Administration Acceptance of Supplemental New Drug Application for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy - Nov 25th, 2024 12:00 pm
BridgeBio heart drug approved by FDA, setting up battle with Pfizer - Nov 22nd, 2024 7:16 pm
ALNY Reports Sustained 6-Month Efficacy Data From Amyloidosis Study - Nov 18th, 2024 2:26 pm
Alnylam reveals trial outcomes of nucresiran for ATTR amyloidosis treatment - Nov 18th, 2024 12:24 pm
Alnylam Announces Interim Phase 1 Data of Nucresiran (ALN-TTRsc04) Showing Rapid Knockdown of TTR that is Sustained at Six Months Following a Single Dose - Nov 17th, 2024 2:30 pm
3 US Stocks Estimated To Be Trading At Discounts Up To 48.8% - Nov 12th, 2024 10:06 am
Top 20 biopharmas’ market cap rises 2% in Q3 2024 amid flurry of drug approvals - Nov 6th, 2024 5:26 pm
An RNAi renaissance is creating a new generation of startups - Nov 6th, 2024 9:27 am
Alnylam to Webcast Presentations at Upcoming November Investor Conferences - Nov 4th, 2024 1:00 pm
Alnylam Q3 Loss In Line With Estimates, Revenues Miss, Stock Down - Nov 1st, 2024 1:32 pm
Alnylam Pharmaceuticals Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Nov 1st, 2024 12:00 pm